Synedgen’s MIIST platform has been developed with extensive funding from the U.S. Army, DARPA, and other partners. This technology has been applied extensively to develop products that meet warfighter needs in combat injuries. Synedgen is developing the next generation of these cutting-edge products for injury to the gut mucosal surface.
Our technology holds the potential to deliver powerful benefits across a wide spectrum of diseases. We thank the following groups for our peer-reviewed funding: